神经药理学报

神经药理学报 ›› 2024, Vol. 14 ›› Issue (3): 47-.DOI: 10.3969/j.issn.2095-1396.2024.03.006

• 研究论文 • 上一篇    下一篇

不同BMI 的特发性矮小症患儿应用重组人生长激素治疗的疗效及安全性分析

张文慧，许峥嵘   

  1. 1. 河北北方学院研究生学院，张家口，075000，中国 

    2. 河北北方学院附属第一医院内分泌科，张家口，075000，中国

  • 出版日期:2024-06-26 发布日期:2024-08-20
  • 作者简介:张文慧，硕士研究生；研究方向：内分泌与代谢病；E-mail: lhlin123@126.com

Efficacy and Safety Analysis of Recombinant Human Growth Hormone Therapy in Children with Idiopathic Short Stature with Different Body Mass Indexes

ZHANG Wen-hui, XU Zheng-rong   

  1. 1. Graduate School, Hebei North University, Zhangjiakou, 075000, China 

    2. Endocrinology Department, The First Affiliated Hospital of Hebei North University, Zhangjiakou, 075000, China

  • Online:2024-06-26 Published:2024-08-20

PDF (PC)

12

摘要：

目的：分析不同体重指数（body mass index, BMI）的特发性矮小症（idiopathic short stature, ISS）患儿在 重组人生长激素（recombinant human growth hormone, rhGH）治疗下的疗效差异及安全性。方法：选取于河北北 方学院附属第一医院接受rhGH 治疗的ISS 患儿为研究对象，根据7 岁以下儿童生长标准及中国6 ～18 岁学龄 儿童青少年性别、年龄、体质指数、超重与肥胖界值，将ISS 患儿分为BMI 正常组、超重组、肥胖组，测定三组患儿 治疗前、治疗3 个月及6 个月后的身高（height, Ht）、BMI、生长速率（growth velocity, GV）、身高标准差积分（height standard deviation score, HtSDS）、胰岛素样生长因子-1（insulin like growth factor-1, IGF-1）、胰岛素样生长因子 结合蛋白-3（insulin like growth factor binding-protein-3, IGFBP-3）、空腹血糖（fasting blood glucose, FBG）、甲状 腺功能及肝功能。结果：三组ISS 患儿在rhGH 治疗后Ht、GV、HtSDS、IGF-1、IGFBP-3 均较治疗前增加（P<0.05）。 BMI 正常组患儿Ht、GV 和HtSDS 增长量明显高于超重组及肥胖组（P <0.05），超重组与肥胖组相比无明显差异 （P >0.05）。BMI 正常组患儿在治疗6 个月后BMI 较治疗前增加（P <0.05）, 而超重组及肥胖组BMI 均较前下降 （P <0.05）。rhGH 治疗对FBG、甲状腺功能、肝功能无明显影响。结论：rhGH 能明显提高ISS 患儿的Ht、HtSDS、 GV、IGF-1、IGFBP-3 水平，BMI 正常的ISS 患儿的疗效明显好于超重组及肥胖组，超重及肥胖ISS 患儿疗效无 明显差异，rhGH 治疗具有较好的安全性。

关键词: 特发性矮小症, 体重指数, 重组人生长激素

Abstract:

Objective：This article aims to analyze the differences in efficacy and safety of recombinant human growth hormone (rhGH) treatment in children with idiopathic short stature (ISS) with different body mass indexes (BMI). Methods: ISS patients who received rhGH treatment at the First Affiliated Hospital of Hebei North University were selected as the research subjects. According to the growth standards for children under 7 years old and the gender age specific body mass index (BMI) overweight and obesity thresholds for Chinese school aged children and adolescents aged 6~18, ISS patients were divided into normal BMI group, overweight group and obese group. The height (Ht), body mass index (BMI), growth velocity (GV), height standard deviation score (HtSDS), insulin like growth factor-1 (IGF-1), insulin like growth factor binding-protein-3 (IGFBP-3), fasting blood glucose (FBG), thyroid function and liver function of three groups were measured before treatment, 3 months after treatment, and 6 months after treatment. Results: After rhGH treatment, the levels of Ht, GV, HtSDS, IGF-1, and IGFBP-3 in the three groups of ISS patients increased compared to before treatment (P<0.05). The amount of increase in Ht, GV, and HtSDS in children with normal BMI were significantly higher than those in the overweight and obese groups (P<0.05), while there was no significant difference between the overweight group and obese group (P>0.05). After 6 months of treatment, the BMI of children with normal BMI increased compared to before treatment (P<0.05), while the BMI of overweight group and obese group decreased compared to before (P<0.05). rhGH treatment has no significant effect on fasting blood glucose, thyroid function and liver function. Conclusion: rhGH can significantly increase the levels of Ht, HtSDS, GV, IGF-1, and IGFBP-3 in children with ISS. The therapeutic effect of ISS patients with normal BMI is significantly better than that of overweight group and obese group. There is no significant difference in the therapeutic effect between overweight and obese ISS patients, and rhGH treatment has great safety.

Key words: idiopathic short stature, body mass index, recombinant human growth hormone

中图分类号: